- Home
- USIO vs CALC Comparison
USIO vs CALC Comparison
Compare USIO & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USIO
- CALC
- Stock Information
- Founded
- USIO 1998
- CALC 2011
- Country
- USIO United States
- CALC United States
- Employees
- USIO N/A
- CALC N/A
- Industry
- USIO Investment Bankers/Brokers/Service
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- USIO Finance
- CALC Health Care
- Exchange
- USIO Nasdaq
- CALC Nasdaq
- Market Cap
- USIO 37.8M
- CALC 44.7M
- IPO Year
- USIO N/A
- CALC N/A
- Fundamental
- Price
- USIO $1.47
- CALC $3.45
- Analyst Decision
- USIO Strong Buy
- CALC Strong Buy
- Analyst Count
- USIO 2
- CALC 4
- Target Price
- USIO $5.00
- CALC $19.50
- AVG Volume (30 Days)
- USIO 81.8K
- CALC 97.8K
- Earning Date
- USIO 11-06-2024
- CALC 11-13-2024
- Dividend Yield
- USIO N/A
- CALC N/A
- EPS Growth
- USIO N/A
- CALC N/A
- EPS
- USIO 0.13
- CALC N/A
- Revenue
- USIO $81,027,258.00
- CALC N/A
- Revenue This Year
- USIO $4.13
- CALC N/A
- Revenue Next Year
- USIO $13.76
- CALC N/A
- P/E Ratio
- USIO $11.08
- CALC N/A
- Revenue Growth
- USIO N/A
- CALC N/A
- 52 Week Low
- USIO $1.30
- CALC $2.68
- 52 Week High
- USIO $2.00
- CALC $8.38
- Technical
- Relative Strength Index (RSI)
- USIO 54.32
- CALC 42.37
- Support Level
- USIO $1.40
- CALC $3.27
- Resistance Level
- USIO $1.55
- CALC $3.47
- Average True Range (ATR)
- USIO 0.06
- CALC 0.14
- MACD
- USIO 0.00
- CALC 0.01
- Stochastic Oscillator
- USIO 61.90
- CALC 42.86
About USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for the Output Solutions operations.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.